

39. (Amended) A method of making a concatamerised polypeptide, the method comprising expressing the nucleic acid sequence of claim 24; isolating an expressed polypeptide having a unique cysteine residue; and conjugating the unique cysteine residue in the isolated polypeptide through a chemical linkage to an antigen molecule comprising one or more thiol-reactive functions.
40. (Amended) A method of making an antigen derivative, the method comprising expressing the nucleic acid sequence of 24 with a unique unpaired cysteine; separately expressing or preparing an antigen derivative with one or more unpaired cysteines; linking the two entities through an intermolecular disulphide bond; and isolating the product.
41. (Twice Amended) A composition comprising a pharmaceutically acceptable carrier and the nucleic acid sequence of claim 23.
42. (Amended) A composition comprising a pharmaceutically acceptable carrier and the expression vector of claim 30.